Overview
- Product nameAnti-p21 antibodySee all p21 primary antibodies ...
- DescriptionRabbit polyclonal to p21
- Tested applicationsWB more details
- Species reactivityReacts with: Human
- Immunogen
Synthetic peptide selected from the S130 region of Human p21, conjugated to KLH.
- Positive controlHeLa cell lysate
Properties
- FormLiquid
- Storage instructionsStore at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freeze / thaw cycles.
- Storage bufferPreservative: 0.09% Sodium Azide
Constituents: PBS -
Concentration information loading... - PurityImmunogen affinity purified
- Purification notesPurified through a protein A column, followed by peptide affinity purification.
- Clonality Polyclonal
- IsotypeIgG
- Research Areas
Applications
Our Abpromise guarantee covers the use of ab102635 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
| Application | Notes |
|---|---|
| WB | WB: 1/100 - 1/500. Predicted molecular weight: 18 kDa. |
Target
- FunctionMay be the important intermediate by which p53/TP53 mediates its role as an inhibitor of cellular proliferation in response to DNA damage. Binds to and inhibits cyclin-dependent kinase activity, preventing phosphorylation of critical cyclin-dependent kinase substrates and blocking cell cycle progression. Functions in the nuclear localization and assembly of cyclin D-CDK4 complex and promotes its kinase activity towards RB1. At higher stoichiometric ratios, inhibits the kinase activity of the cyclin D-CDK4 complex.
- Tissue specificityExpressed in all adult human tissues, with 5-fold lower levels observed in the brain.
- Sequence similaritiesBelongs to the CDI family.
- DomainThe PIP-box K+4 motif mediates both the interaction with PCNA and the recuitment of the DCX(DTL) complex: while the PIP-box interacts with PCNA, the presence of the K+4 submotif, recruits the DCX(DTL) complex, leading to its ubiquitination.
The C-terminal is required for nuclear localization of the cyclin D-CDK4 complex. - Post-translational
modificationsPhosphorylation of Thr-145 by Akt or of Ser-146 by PKC impairs binding to PCNA. Phosphorylation at Ser-114 by GSK3-beta enhances ubiquitination by the DCX(DTL) complex.
Ubiquitinated by MKRN1; leading to polyubiquitination and 26S proteasome-dependent degradation. Ubiquitinated by the DCX(DTL) complex, also named CRL4(CDT2) complex, leading to its degradation during S phase or following UV irradiation. Ubiquitination by the DCX(DTL) complex is essential to control replication licensing and is PCNA-dependent: interacts with PCNA via its PIP-box, while the presence of the containing the 'K+4' motif in the PIP box, recruit the DCX(DTL) complex, leading to its degradation. - Cellular localizationCytoplasm. Nucleus.
-
Database links
- Entrez Gene: 1026 Human
- Omim: 116899 Human
- SwissProt: P38936 Human
- Unigene: 370771 Human
Target information above from: UniProt accession
P38936
The UniProt Consortium
The Universal Protein Resource (UniProt) in 2010
Nucleic Acids Res. 38:D142-D148 (2010)
.
-
Alternative names
- CAP20 antibodyCDK-interacting protein 1 antibodyCDKI antibody
- CDKN1 antibodyCDKN1A antibodyCDN1A_HUMAN antibodyCIP1 antibodyCyclin Dependent Kinase Inhibitor 1A antibodyCyclin-dependent kinase inhibitor 1 antibodyCyclin-dependent kinase inhibitor 1A (P21) antibodyCyclin-dependent kinase inhibitor 1A (p21, Cip1) antibodyDNA Synthesis Inhibitor antibodyMDA-6 antibodyMDA6 antibodyMelanoma differentiation-associated protein 6 antibodyMelanoma differentiation-associated protein antibodyp21 antibodyP21 protein antibodyp21CIP1 antibodyp21Cip1/Waf1 antibodyp21WAF antibodySDI1 antibodyWAF1 antibodyWild type p53 activated fragment 1 antibodyWildtype p53-activated fragment 1 antibody
see all
Anti-p21 antibody images
-
Anti-p21 antibody (ab102635) at 1/100 dilution + HeLa cell lysate at 35 µg
Predicted band size : 18 kDa
References for Anti-p21 antibody (ab102635)
ab102635 has not yet been referenced specifically in any publications.
